Hyperliquid Strategies Inc (PURR) Stock Price, Quote & News

Company Profile

Hyperliquid Strategies Inc. operates as a digital asset treasury company focused on the blockchain and cryptocurrency sector. The company provides investors exposure to the HYPE token through treasury management strategies, such as token accumulation, staking, and yield optimization within the Hyperliquid ecosystem. The company was incorporated in 2025 and is based in New York, New York.

Industry: Capital Markets

Sector: Financial Services

Phone: 212-883-4330

Website: www.hypestrat.xyz

Address:

477 Madison Avenue, 22nd Floor, New York, United States

TICKERTUTOR Apr. 5 at 1:47 PM

$SPY Never really know for sure where futs will open at 6P. but this might be a decent guide. #HYPERLIQUID $PURR https://app.trade.xyz/?market=SP500

0 · Reply

Nosh Apr. 2 at 7:36 PM

$PURR Added.

0 · Reply

mikeonhl Apr. 2 at 2:07 AM

Genuine question....I hold both $PURR and $HYPE.X ... Is that a little redundant? With the stock, I can't do much with it but hold it. It has way more market growth potential. With the token, I can use it as collateral on hyperliquid and trade perps or stock...or even stake it. It already has a higher market cap but could 3-5x. Which one would sell if you had to hold just one? $BTC.X $SOL.X $CRCL

1 · Reply

hugoraciel Apr. 1 at 11:49 PM

$PURR ima assume this is crazy manipulated

1 · Reply

mikeonhl Apr. 1 at 8:20 PM

$HYPE.X $PURR.X $PURR $BTC.X $SPY hyperliquid launched a (beta) app. Be sure to install the one made from "hyperliquid corporation"! There are already fake apps. Don't get drained. To access in restricted area...use VPN, create new Play store account with VPN on, then install the app. Gl

0 · Reply

basebreakouts Apr. 1 at 6:17 PM

$PURR this is going to rocket when HYPE reaches new highs

0 · Reply

mikeonhl Apr. 1 at 5:10 PM

$PURR can't wait to see this at $ 30 this fall

0 · Reply

drewboca Apr. 1 at 4:08 PM

$PURR it's also hilarious to listen to him explain why having his treasury stock is important to hyperliquid

0 · Reply

drewboca Apr. 1 at 3:38 PM

$PURR I like hype but the CEO of purr sounds like an idiot if you know anything about finance. He keeps comparing perpetual futures to options as if their the same because Robin Hood does a lot of options.

1 · Reply

hugoraciel Apr. 1 at 1:43 PM

$PURR Projected Next Peak: ∙ $10–$14 range ∙ Timeline: Mid-to-late April 2026 ∙ The Mar 18 spike to $6.38 proved the asset can make violent upside moves Target ladder: ∙ $8.50 → first resistance ∙ $10.00 → psychological breakout ∙ $14.00 → full cycle target The structure is screaming higher.

0 · Reply

Hyperliquid Strategies Inc. Announces Milestone with Launch of Options Trading on PURR Common Stock

Feb 11, 2026, 6:45 AM EST - 7 weeks ago

Hyperliquid Strategies Inc Reports Financial Results for the Quarter Ended December 31, 2025

Feb 5, 2026, 4:15 PM EST - 2 months ago

Hyperliquid Strategies Inc Announces Webcast to Discuss Results for the Quarter Ended December 31, 2025

Dec 8, 2025, 9:20 AM EST - 4 months ago

Hyperliquid Strategies Inc Announces $30 million Stock Repurchase Program

Dec 3, 2025, 5:45 PM EST - 4 months ago

Ex-Barclays CEO unpacks Hyperliquid: ‘The FUTURE of finance'

Dec 2, 2025, 4:30 PM EST - 4 months ago

Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination

Nov 18, 2025, 9:00 AM EST - 4 months ago

Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting

Oct 15, 2025, 10:03 AM EDT - 6 months ago

Evaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with Sarcoma

Sep 19, 2025, 9:00 AM EDT - 7 months ago

Sonnet to Present at the MedInvest Biotech & Pharma Conference

Aug 11, 2025, 9:15 AM EDT - 8 months ago

Sonnet Releases Virtual Investor "What This Means" Segment

Aug 4, 2025, 8:40 AM EDT - 8 months ago

Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer

Jul 14, 2025, 11:30 AM EDT - 9 months ago

Why Is Sonnet BioTherapeutics Stock Trading Higher On Monday?

Jul 14, 2025, 6:00 AM EDT - 9 months ago

Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy

May 1, 2025, 9:00 AM EDT - 1 year ago

Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit

Apr 4, 2025, 9:00 AM EDT - 1 year ago

Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

Apr 1, 2025, 4:15 PM EDT - 1 year ago

Sonnet Announces Release of Corporate Update Video

Apr 1, 2025, 7:30 AM EDT - 1 year ago

Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.

Mar 26, 2025, 9:05 AM EDT - 1 year ago

Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

Mar 19, 2025, 8:50 AM EDT - 1 year ago

Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein

Mar 11, 2025, 8:45 AM EDT - 1 year ago

Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 26, 2025, 9:00 AM EST - 1 year ago

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors

Feb 19, 2025, 8:35 AM EST - 1 year ago

Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates

Feb 18, 2025, 9:15 AM EST - 1 year ago

Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference

Feb 13, 2025, 8:30 AM EST - 1 year ago

Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer

Feb 13, 2025, 8:00 AM EST - 1 year ago

Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update

Jan 28, 2025, 9:05 AM EST - 1 year ago

Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology

Jan 22, 2025, 8:35 AM EST - 1 year ago

Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Jan 21, 2025, 9:05 AM EST - 1 year ago

Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas

Dec 23, 2024, 9:20 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment

Dec 17, 2024, 8:50 AM EST - 1 year ago

Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Dec 9, 2024, 3:42 PM EST - 1 year ago

Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 9, 2024, 8:45 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial

Dec 4, 2024, 9:20 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action

Nov 12, 2024, 9:15 AM EST - 1 year ago

Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment

Nov 6, 2024, 1:20 PM EST - 1 year ago

Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules

Nov 6, 2024, 8:30 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates

Oct 17, 2024, 8:45 AM EDT - 1 year ago

Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq

Oct 9, 2024, 8:45 AM EDT - 1 year ago

Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India

Oct 4, 2024, 8:30 AM EDT - 1 year ago

Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs

Sep 30, 2024, 9:00 AM EDT - 1 year ago

Sonnet BioTherapeutics Announces Launch of CEO Corner Platform

Sep 25, 2024, 8:30 AM EDT - 1 year ago

Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split

Sep 18, 2024, 8:30 AM EDT - 1 year ago

Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors

Sep 4, 2024, 9:15 AM EDT - 1 year ago

Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series

Aug 19, 2024, 8:45 AM EDT - 1 year ago

Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer

Aug 14, 2024, 8:35 AM EDT - 1 year ago

Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Jul 24, 2024, 3:00 PM EDT - 1 year ago

Sonnet BioTherapeutics (NASDAQ:SONN) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team

Jul 24, 2024, 8:30 AM EDT - 1 year ago

Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study

May 28, 2024, 8:00 AM EDT - 2 years ago

Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting

May 20, 2024, 9:15 AM EDT - 2 years ago

Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target

TICKERTUTOR Apr. 5 at 1:47 PM

$SPY Never really know for sure where futs will open at 6P. but this might be a decent guide. #HYPERLIQUID $PURR https://app.trade.xyz/?market=SP500

0 · Reply

Nosh Apr. 2 at 7:36 PM

$PURR Added.

0 · Reply

mikeonhl Apr. 2 at 2:07 AM

1 · Reply

hugoraciel Apr. 1 at 11:49 PM

$PURR ima assume this is crazy manipulated

1 · Reply

mikeonhl Apr. 1 at 8:20 PM

0 · Reply

basebreakouts Apr. 1 at 6:17 PM

$PURR this is going to rocket when HYPE reaches new highs

0 · Reply

mikeonhl Apr. 1 at 5:10 PM

$PURR can't wait to see this at $ 30 this fall

0 · Reply

drewboca Apr. 1 at 4:08 PM

$PURR it's also hilarious to listen to him explain why having his treasury stock is important to hyperliquid

0 · Reply

drewboca Apr. 1 at 3:38 PM

1 · Reply

hugoraciel Apr. 1 at 1:43 PM

0 · Reply

CestrianCapitalResearch Apr. 1 at 12:59 PM

$HYPE.X $PURR note on our site today. No paywall.

0 · Reply

mikeonhl Apr. 1 at 12:46 PM

$HYPE.X $PURR wow continues to trade against the market bearishness

0 · Reply

mikeonhl Apr. 1 at 11:53 AM

$BTC.X word on the street is that crypto spring is starting... $SOL.X $HYPE.X $PURR

0 · Reply

Jackie_Treehorn Mar. 31 at 10:56 PM

$HYPE.X $PURR $PURR.X so it’s fair to say that PURR can hit $20-$25?

1 · Reply

mikeonhl Mar. 31 at 8:05 PM

$HYPE.X $PURR $PURR.X https://youtu.be/UCJdMSeU0TA?si=DNStkRqa2T9sY8ZD

0 · Reply

hugoraciel Mar. 31 at 5:23 PM

$PURR In short, PURR is essentially a crypto treasury play — its stock price moves closely with the HYPE token, and the March 30 gap-up reflects ongoing volatility tied to crypto market movements and investor sentiment.

0 · Reply

hugoraciel Mar. 31 at 5:22 PM

$PURR The company deployed $129.5 million to acquire approximately 5 million additional HYPE tokens by February 2026, bringing total holdings to 17.6 million tokens. The HYPE token itself surged nearly 49% in the month leading up to late March 2026, directly boosting the company’s valuation.

0 · Reply

drewboca Mar. 31 at 4:59 PM

$PURR does this company still due biotech? If not why don't they update website.

0 · Reply

Dirtdemon75 Mar. 31 at 2:27 PM

$PURR

0 · Reply

sejame Mar. 31 at 11:55 AM

$PURR ready to see this explode. With market down im officially out of fuel to add but expecting to be able to load more shares soon.

0 · Reply

mikeonhl Mar. 31 at 8:15 AM

$PURR I bought pre-market on webull. Buying under $ 5 a gift

0 · Reply

mikeonhl Mar. 31 at 3:13 AM

$PURR $PURR.X $HYPE.X I just learned about hype being a regulated stock and they have a memecoin and options on NASDAQ now!? Wtf. Gold mine. I'm fucking loading the boat 🚢

0 · Reply

Market Cap	613.64M
Revenue (ttm)	1.00M
Net Income (ttm)	-16.01M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,601.00%
Debt to Equity Ratio	0.00

Volume	3,666,800
Avg Vol	4,872,706
Day's Range	N/A - N/A
Shares Out	123.97M
Stochastic %K	28%
Beta	1.38
Analysts	Strong Sell
Price Target	$7.22